文献速递支持与姑息治疗骨软组织肉瘤与黑色素瘤

高血清LDH和肝转移是抗PD(L)1免疫治疗原发性耐药的主要预测因素

High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy.
PubMed 文献 · Eur J Cancer · 2022-09-30

该回顾性预后/预测研究分析695例晚期癌症患者的33项基线常规医学变量,采用随机森林模型和多因素分析。结果显示,LDH升高(LDHhi)和肝转移(LM+)是短总生存期的独立预测因素;抗PD-(L)1单药治疗中,LDHhiLM+患者中位OS为3.1个月,LDHlowLM-患者为15.3个月(P<0.0001)。作者认为LDHhiLM+状态可识别不能从抗PD-(L)1单药治疗中获益的患者。

要点

  • LDHhi和LM+是晚期癌症患者接受抗PD-(L)1单药治疗后短OS的独立预测因素。
  • 抗PD-(L)1单药治疗中,LDHhiLM+患者中位OS 3.1个月 vs LDHlowLM-患者15.3个月(P<0.0001)。
  • 总体人群中,免疫治疗LDHlowLM-患者中位OS 28.8个月 vs 其他系统治疗13.1个月(P=0.02)。

核心结论

  • LDHhiLM+状态可识别不能从抗PD-(L)1单药治疗中获益的患者,可用于临床试验中对患者进行分层并最终解决这一特定医疗需求。

研究设计与样本

  • 该回顾性预后/预测研究分析了来自CT图像、临床和生物学元数据的33项基线常规医学变量。
  • 695例诊断为晚期癌症的患者在单一三级癌症中心的前瞻性临床试验中接受治疗,分为3个队列:系统性抗PD-(L)1治疗251例、235例 vs 其他系统治疗209例。

主要发现

  • LDHhi和LM+是黑色素瘤和非黑色素瘤实体瘤独立队列中短OS的主要且独立预测因素。
  • 抗PD-(L)1单药治疗中,LDHhiLM+患者中位OS为3.1[2.4-7.8]个月,LDHlowLM-患者中位OS为15.3[8.9-NA]个月(P<0.0001)。
  • 总体人群中,免疫治疗LDHlowLM-患者中位OS为28.8[17.9-NA]个月 vs 其他系统治疗13.1[10.8-18.5]个月(P=0.02)。
  • 黑色素瘤患者中,免疫治疗LDHlowLM-患者中位OS为30.3[19.93-NA]个月 vs 其他系统治疗14.1[8.69-NA]个月(P=0.0013)。

临床怎么用

  • 作者认为LDHhiLM+状态可用于临床试验中对患者进行分层,并最终解决这一特定医疗需求。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Anti-PD-(L)1 immunotherapies improve survival in multiple cancers but remain ineffective for most patients. We applied machine-learning algorithms and multivariate analyses on baseline medical data to estimate their relative impact on overall survival (OS) upon anti-PD-(L)1 monotherapies. METHOD: This prognostic/predictive study retrospectively analysed 33 baseline routine medical variables derived from computed tomography (CT) images, clinical and biological meta-data. 695 patients with a diagnosis of advanced cancer were treated in prospective clinical trials in a single tertiary cancer centre in 3 cohorts including systemic anti-PD-(L)1 (251, 235 patients) versus other systemic therapies (209 patients). A random forest model combined variables to identify the combination (signature) which best estimated OS in patients treated with immunotherapy. The performance for estimating OS [95%CI] was measured using Kaplan-Meier Analysis and Log-Rank test. RESULTS: Elevated serum lactate dehydrogenase (LDHhi) and presence of liver metastases (LM+) were dominant and independent predictors of short OS in independent cohorts of melanoma and non-melanoma solid tumours. Overall, LDHhiLM+ patients treated with anti-PD-(L)1 monotherapy had a poorer outcome (median OS: 3.1[2.4-7.8] months]) compared to LDHlowLM-patients (median OS: 15.3[8.9-NA] months; P < 0.0001). The OS of LDHlowLM-patients treated with immunotherapy was 28.8[17.9-NA] months (vs 13.1[10.8-18.5], P = 0.02) in the overall population and 30.3[19.93-NA] months (vs 14.1[8.69-NA], P = 0.0013) in patients with melanoma. CONCLUSION: LDHhiLM+ status identifies patients who shall not benefit from anti-PD-(L)1 monotherapy. It could be used in clinical trials to stratify patients and eventually address this specific medical need.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dercle L, Ammari S, Roblin E, et al. High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. Eur J Cancer. 2022. PMID: 36332438. doi:10.1016/j.ejca.2022.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。